



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Etrinabdione

|                    |                                                                                                                          |
|--------------------|--------------------------------------------------------------------------------------------------------------------------|
| Cat. No.:          | HY-128872                                                                                                                |
| CAS No.:           | 1818428-24-8                                                                                                             |
| Molecular Formula: | C <sub>28</sub> H <sub>35</sub> NO <sub>3</sub>                                                                          |
| Molecular Weight:  | 433.58                                                                                                                   |
| Target:            | PPAR; Cannabinoid Receptor; HIF/HIF Prolyl-Hydroxylase                                                                   |
| Pathway:           | Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor; GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease |
| Storage:           | Powder    -20°C    3 years<br>4°C    2 years<br>In solvent   -80°C    6 months<br>-20°C    1 month                       |



### SOLVENT & SOLUBILITY

|                                                                               |                                                                                                                                                  |                                                       |      |           |            |            |
|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|------|-----------|------------|------------|
| In Vitro                                                                      | DMSO : 50 mg/mL (115.32 mM; Need ultrasonic)                                                                                                     |                                                       |      |           |            |            |
|                                                                               | Preparing Stock Solutions                                                                                                                        | <div><div>Solvent</div><div>Concentration</div></div> | Mass | 1 mg      | 5 mg       | 10 mg      |
|                                                                               |                                                                                                                                                  | 1 mM                                                  |      | 2.3064 mL | 11.5319 mL | 23.0638 mL |
|                                                                               |                                                                                                                                                  | 5 mM                                                  |      | 0.4613 mL | 2.3064 mL  | 4.6128 mL  |
|                                                                               |                                                                                                                                                  | 10 mM                                                 |      | 0.2306 mL | 1.1532 mL  | 2.3064 mL  |
| Please refer to the solubility information to select the appropriate solvent. |                                                                                                                                                  |                                                       |      |           |            |            |
| In Vivo                                                                       | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline<br>Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution         |                                                       |      |           |            |            |
|                                                                               | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)<br>Solubility: 2.5 mg/mL (5.77 mM); Suspended solution; Need ultrasonic |                                                       |      |           |            |            |
|                                                                               | 3. Add each solvent one by one: 10% DMSO >> 90% corn oil<br>Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution                                    |                                                       |      |           |            |            |

### BIOLOGICAL ACTIVITY

|                           |                                                                                                                                                                                                                                                                                                                                                                                                         |                 |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Description               | Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPAR $\gamma$ and CB <sub>2</sub> receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity <sup>[1][2]</sup> . |                 |
| IC <sub>50</sub> & Target | PPAR $\gamma$                                                                                                                                                                                                                                                                                                                                                                                           | CB <sub>2</sub> |

## In Vivo

Etrinabdone (i.p.; 20 mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice. Etrinabdone can also significantly ameliorate glucose tolerance, reduce leptin levels (a marker of adiposity) and increase adiponectin and incretins (GLP-1 and GIP) levels<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

- [1]. Navarrete C, et al. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. J Neuroinflammation. 2018 Mar 1;15(1):64.
- [2]. Palomares B, et al. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. Sci Rep. 2018 Oct 31;8(1):16092.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA